Insider Bellon at Beam (NASDAQ: BEAM) sells shares via 10b5-1 plan

Rhea-AI Filing Summary

Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported sales of company common stock in open-market transactions on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.

She sold blocks of Beam common stock at weighted-average prices of $33.6219, $34.7182 and $35.3988, with each price reflecting multiple trades within disclosed ranges. Following these sales, Bellon directly beneficially owned 97,038 shares of Beam common stock.

Insider Trade Summary

Net Seller: 18,629 shares ($644,832)

Net Sell 3 txns

Insider Bellon Christine

Role Chief Legal Officer

Sold 18,629 shs ($645K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,111	$33.6219	$71K
Sale	Common Stock	15,959	$34.7182	$554K
Sale	Common Stock	559	$35.3988	$20K

Holdings After Transaction: Common Stock — 113,556 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.17 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.355 to $35.34, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.38 to $35.485, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Christine

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S(1)		2,111	D	$33.6219(2)	113,556	D
Common Stock	01/15/2026		S(1)		15,959	D	$34.7182(3)	97,597	D
Common Stock	01/15/2026		S(1)		559	D	$35.3988(4)	97,038	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.17 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.355 to $35.34, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.38 to $35.485, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	By: /s/ Christine Bellon	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider reporting this Form 4 transaction for BEAM?

The reporting person is Christine Bellon, who serves as Chief Legal Officer of Beam Therapeutics Inc. (BEAM).

What type of BEAM securities did Christine Bellon sell and on what date?

Christine Bellon sold Beam Therapeutics common stock in open-market transactions on January 15, 2026, as reported in Table I of the Form 4.

At what prices were the BEAM shares sold in this Form 4 filing?

The reported sales used weighted-average prices of $33.6219, $34.7182 and $35.3988 per share, each representing multiple trades within specified price ranges.

How many BEAM shares does Christine Bellon own after the reported transactions?

After the January 15, 2026 transactions, Christine Bellon beneficially owned 97,038 shares of Beam Therapeutics common stock in direct ownership.

Were the BEAM stock sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan that Christine Bellon adopted on September 16, 2025.

What do the weighted-average prices in the BEAM Form 4 mean?

Each weighted-average price reflects multiple individual trades within a disclosed price range, and the reporting person has undertaken to provide details of the number of shares sold at each separate price upon request.